AXSOME THERAPEUTICS, INC. Repayments of Long-Term Debt
AXSOME THERAPEUTICS, INC. (AXSM) reported Repayments of Long-Term Debt of $140.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2026-06-30 was $70.00M.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2026-03-31 was $70.00M.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2025-12-31 was $70.00M.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2025-09-30 was $70.00M.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for fiscal 2025 was $331.99M.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for fiscal 2020 was $21.66M, a 199.22% increase from fiscal 2019.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for fiscal 2019 was $7.24M, a 117.17% increase from fiscal 2018.
- AXSOME THERAPEUTICS, INC. repayments of long-term debt for fiscal 2018 was $3.33M, a 1100.00% increase from fiscal 2017.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $140.00M 10-Q · filed 2026-08-10 | $210.00M derived: sum of 3 quarters · filed 2026-08-10 | $280.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $70.00M 10-Q · filed 2026-05-04 | $140.00M derived: sum of 2 quarters · filed 2026-05-04 | $210.00M derived: sum of 3 quarters · filed 2026-05-04 | |
| 2025-12-31 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $140.00M derived: sum of 2 quarters · filed 2026-02-23 | $331.99M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $70.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $261.99M 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | $191.99M 10-Q · filed 2026-08-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $21.66M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $21.66M 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $7.24M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $7.24M 10-Q · filed 2020-11-05 | $8.07M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $7.24M 10-Q · filed 2020-08-10 | $8.07M derived: sum of 3 quarters · filed 2021-03-01 | $8.91M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $7.24M 10-Q · filed 2020-05-11 | $8.07M derived: sum of 2 quarters · filed 2021-03-01 | $8.91M derived: sum of 3 quarters · filed 2021-03-01 | $9.74M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $833.33K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.67M derived: sum of 2 quarters · filed 2021-03-01 | $2.50M derived: sum of 3 quarters · filed 2021-03-01 | $3.33M 10-K · filed 2021-03-01 |
| 2018-09-30 | $833.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.67M derived: sum of 2 quarters · filed 2019-11-07 | $2.50M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $833.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.67M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $833.33K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $277.78K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |